Six-month symptom control was similar with advanced pneumatic compression and usual care, although some clinician-rated lymphedema measures favored compression.
Two blinded oncologists often assigned different peak toxicity grades, including grade 3 mucositis rates of 40.5% versus 17.6%.
Mean pelvic marrow dose above approximately 24 Gy and V40 above 13% identified higher hematologic toxicity risk during rectal chemoradiotherapy.
Dose to neck skin, subcutaneous tissue, and sternocleidomastoid muscle predicted fibrosis burden in nonsurgical head and neck cancer survivors.
Carbon-ion schedules produced similar tumour outcomes, but sacral insufficiency fractures occurred in 47% versus 24% with 4 Gy(RBE) fractions.
Poor sleep affected 69% of survivors, while 21.4% screened as high risk for obstructive sleep apnoea.
Experts propose selecting radiotherapy–drug regimens using efficacy, scheduling, late toxicity, biomarkers, and patient-reported outcomes rather than maximum tolerated dose alone.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
An MTV threshold of 50 mL identified patients with poorer survival who appeared to benefit from combined-modality treatment.
Only 33% of statements reached consensus, but experts agreed on multimodality imaging, eligible lesions, and daily image guidance.
International experts identified eight research priorities covering biomarker-guided chemoradiation, immunotherapy sequencing, and consolidation radiotherapy in metastatic head and neck cancer.
In 20 vulvar cancer patients, SGRT reduced pitch error from 1.21° to 0.07° and longitudinal error from 4.9 to 0.4 mm.
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Template-guided implantation achieved a median HR-CTV D90 of 92.9 Gy with low severe toxicity across 555 brachytherapy fractions.
Grade ≥2 urinary toxicity fell from 22% at two weeks to 3% at six months, with almost no clinically significant bowel toxicity.